BIM.PA

Full HouseAI neutral

bioMérieux S.A. · Healthcare · France · $11.8B cap · $17.4M/day traded

EUR 90.65 -1.4% · close 17 Nov · scored 18 Nov

Full House: Strong business, sensible price, and the market agrees.

91
Score
Get score and insider alerts
Quality
74
Value
53
Momentum
68

As of 18 Nov 2026, the MoatMap Score for bioMérieux S.A. (BIM.PA) is 91/100, ranked against 25,000+ stocks in 38 markets (Quality 74, Value 53, Momentum 68, each scored against its sector).

Does the score work? Each tenth of the ranking, tracked monthly. See the record →

P/E (TTM)
23.8x
peers 24.1x
ROE
11.2%
peers -69.7%
D/E
0.1x
peers 0.7x
Dividend %
1.1%
trailing yield
AI REVIEW

bioMérieux is a family-controlled leader in in-vitro diagnostics, particularly microbiology and syndromic PCR testing through its BioFire platform. It has a large installed base that drives recurring reagent sales. It is a genuine quality franchise with high switching costs in hospital laboratories. However, forward earnings estimates have edged down about 2% in the past month, and nothing in the current environment points to a catalyst the market has not already priced.

ABOUT BIOMÉRIEUX S.A.

Read

bioMérieux S.A. is a global leader in in vitro diagnostics, providing comprehensive microbiology and immunoassay solutions for clinical and industrial applications. The company holds a significant market share in microbiology diagnostics, driven by its proprietary technology platforms and an extensive global installed base of diagnostic systems. bioMérieux is recognized for its focus on combating infectious diseases and improving patient outcomes through rapid and accurate diagnostic tools.

FINANCIAL SUMMARY (EUR)

Year20212022202320242025CAGRTTM2026E2027EFwd CAGR
Income and shares
Revenue—3.6B3.7B4.0B4.1B4.3%4.0B4.2B4.4B3.8%
Net margin—12.6%9.7%10.9%9.8%-2.8 pts————
EPS (EUR)5.13.83.03.73.4-9.8%3.93.23.40.5%
Share count—117.9M118.2M117.9M118.0M0.0%117.7M———
Balance sheet
Debt—505.4M518.9M490.2M461.4M-3.0%424.7M———
Equity—3.6B3.8B4.2B4.1B4.4%————
Debt/equity—0.1x0.1x0.1x0.1x0.0x————
Cash flow
Op. cash flow—475.1M445.4M667.3M788.4M18.4%911.3M———
Cash flow margin—13.2%12.1%16.8%19.4%+6.2 pts22.7%———
Investing CF—-528.1M-488.8M-359.8M-461.7M—————
Financing CF—-244.2M-122.3M-212.6M-155.4M—————
PRICE (1Y) · EUR+12.3%
80.484.789.093.397.77 Oct28 Oct17 Nov
SMA 50SMA 200

Price checkTurning upExperimental

38% above its 52-week low and back above a rising 50-day average.

SwingsAverage

Calmer than 72% of stocks we rank over the past year (volatility 31% a year).

How this is worked out

The Price check reads only the chart, the price side of the Momentum score in words; it is not the MoatMap Score.

  • Still falling: It set a new 52-week low in the last two weeks, after a deep fall.
  • Finding a floor: It fell hard, but has set no new low for more than two weeks.
  • Turning up (this stock): It has climbed off its low and is back above a rising 50-day average.
  • In an uptrend: It is near its 52-week high and above its 200-day average.
  • No clear trend: None of the above: no recent deep fall and no steady climb.
  • No read yet: Not enough price history yet: it needs a year of trading.

In past US falls, waiting for Turning up cut the chance of another 20% drop from 42% to 33%. Returns were no better, and 33% of turns failed.

The exact rules

Still falling is a new 52-week low in the last two weeks, at least 25% below the high, with the low set after the high. Finding a floor is the same fall with no new low in the last two weeks. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average, with the 50-day average above the 200-day, and within 15% of the high. No clear trend is everything else. No read yet is under 252 trading days of history, or missing data. A new state shows once it has held for three trading days.

In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.

What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.

What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.

Calm is not safe: a calm stock can still slide steadily.

Rules fixed before any data was fetched. Describes the chart, not a recommendation.

Close
EUR 90.65
RSI (14)
49.1
52-Week Range-20.8% from high
Low EUR 65.60High EUR 114.53

SCORE BREAKDOWN

Quality
74
ROIC
12.0%74.1
ROE
11.2%72.6
GP/Assets
38.1%76.1
Op. Margin
16.0%77.5
FCF/Assets
8.1%81.2
Piotroski
784.1
Int. Cover
34.3x76.3
D/E Ratio
0.10x62.2
Current Ratio
2.30x44.7
Value
53
P/E (TTM)
23.8x49.2
EV/EBITDA
10.2x65.7
P/FCF
22.3x50.8
P/B
2.5x47.9
P/S
2.7x56.1
Div Yield
1.1%37.4
Momentum
68
52W High %
79%70.9
RS 6M
23%79.5
SMA 50/200
1.05x71.9
EPS Rev 4W
+0.3%72.5
EPS Rev 12W
+2.0%67.8
EPS Improve
+20%36.4
Q Growth
40%71.0

FUNDAMENTALS

Market Cap
$11.8B
P/E (Forward)
19.8x
Gross Margin
56.1%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BIM.PA are excluded.

TickerCompanyMkt CapScore
BIM.PAbioMérieux S.A.(you)$11.8B91
LBIRD.PALumibird SA$571M49
IPN.PAIpsen S.A.$14.0B95
VIRP.PAVirbac SA$3.3B87
DIM.PASartorius Stedim Biotech S.A.$23.0B64
SNYSanofi$99.7B95
VETO.PAVetoquinol SA$1.0B95
EQS.PAEquasens Société anonyme$499M84
BOI.PABoiron SA$348M89
EL.PAEssilorLuxottica Société anonyme$93.1B56

Peer medians: ROE -69.7% · P/E 24.1x · Gross margin 69.3%

Company Deep Dive

A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.

Request Deep Dive(50 Feathers)

bioMérieux S.A. (BIM.PA): Stock Score Summary

bioMérieux S.A. (BIM.PA) has a MoatMap Score of 91/100 based on Quality (74/100), Value (53/100), and Momentum (68/100) factor scores. bioMérieux is a family-controlled leader in in-vitro diagnostics, particularly microbiology and syndromic PCR testing through its BioFire platform. It has a large installed base that drives recurring reagent sales. It is a genuine quality franchise with high switching costs in hospital laboratories. However, forward earnings estimates have edged down about 2% in the past month, and nothing in the current environment points to a catalyst the market has not already priced.

bioMérieux S.A. is a global leader in in vitro diagnostics, providing comprehensive microbiology and immunoassay solutions for clinical and industrial applications. The company holds a significant market share in microbiology diagnostics, driven by its proprietary technology platforms and an extensive global installed base of diagnostic systems. bioMérieux is recognized for its focus on combating infectious diseases and improving patient outcomes through rapid and accurate diagnostic tools.

Director dealings

From 19 Feb 2026 to 18 Nov 2026, MoatMap's records hold 3 sales and no purchases of bioMérieux S.A. (BIM.PA) shares by its directors. The largest: Pierre BOULUD sold 7,978 shares at EUR 95.00 on 4 Nov 2026 (about EUR 758K).

  • 4 Nov 2026: Bouhours Guillaume sold 3,000 shares at EUR 97.25 (about EUR 292K)
  • 4 Nov 2026: GUILLAUME BOUHOURS sold 3,000 shares at EUR 97.25 (about EUR 292K)
  • 4 Nov 2026: Pierre BOULUD sold 7,978 shares at EUR 95.00 (about EUR 758K)
BIM.PA insider filings, last 180 days

Key Financial Metrics

PriceEUR 90.65
Market Cap$11.8B
P/E (TTM)23.79
P/E (Forward)19.80
Price/Book2.54
Return on Equity11.2%
Return on Invested Capital12.0%
Debt/Equity0.10x
Gross Margin56.1%
Operating Margin16.0%
Revenue Growth-3.9%
Dividend Yield1.1%
Free Cash Flow$528M

bioMérieux S.A. operates in the Diagnostics & Research industry, part of the Healthcare sector (France).

Frequently Asked Questions

What is bioMérieux S.A.’s (BIM.PA) MoatMap Score?
The MoatMap Score for bioMérieux S.A. (BIM.PA) is 91/100. It is a composite of Quality (74), Value (53), and Momentum (68), each scored against its sector. The composite is then ranked across MoatMap’s universe of 25,000+ stocks.
Does bioMérieux S.A. have an economic moat?
bioMérieux S.A. (BIM.PA) has a Quality factor score of 74/100. Quality blends several measures of profitability and financial strength, led by gross profit to assets, return on invested capital and free cash flow to assets. A high score describes the financial record a durable advantage tends to leave; it does not prove a moat.
What sector is bioMérieux S.A. in?
bioMérieux S.A. (BIM.PA) operates in the Healthcare sector, specifically the Diagnostics & Research industry (France).